Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study - Butzkueven, H; Licata, S; Jeffery, D; Arnold, DL; Filippi, M; Geurts, JJ (BMJ Open, 2020)